[go: up one dir, main page]

TW200738240A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
TW200738240A
TW200738240A TW095142635A TW95142635A TW200738240A TW 200738240 A TW200738240 A TW 200738240A TW 095142635 A TW095142635 A TW 095142635A TW 95142635 A TW95142635 A TW 95142635A TW 200738240 A TW200738240 A TW 200738240A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical compositions
disclosed
compositions
opioids
otic
Prior art date
Application number
TW095142635A
Other languages
English (en)
Inventor
Robert Simmons
Allan Weingarten
Yuping Li
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37745944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200738240(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of TW200738240A publication Critical patent/TW200738240A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095142635A 2005-11-21 2006-11-17 Pharmaceutical compositions TW200738240A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73852405P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
TW200738240A true TW200738240A (en) 2007-10-16

Family

ID=37745944

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095142635A TW200738240A (en) 2005-11-21 2006-11-17 Pharmaceutical compositions

Country Status (17)

Country Link
US (2) US20070116730A1 (zh)
EP (2) EP1954275A2 (zh)
JP (2) JP2009516687A (zh)
KR (1) KR20080071185A (zh)
CN (1) CN101312730A (zh)
AR (1) AR058193A1 (zh)
AU (1) AU2006316607A1 (zh)
BR (1) BRPI0618891A2 (zh)
CA (2) CA2629560A1 (zh)
EC (1) ECSP088461A (zh)
NO (1) NO20082833L (zh)
NZ (1) NZ568313A (zh)
PE (1) PE20070643A1 (zh)
RU (1) RU2008124805A (zh)
TW (1) TW200738240A (zh)
WO (2) WO2007061739A2 (zh)
ZA (2) ZA200804305B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647533A1 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
KR20150050595A (ko) 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
BRPI0818483A2 (pt) * 2007-11-01 2015-04-14 Bausch & Lomb Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
MX2010013946A (es) * 2008-06-24 2011-02-15 Intervet Int Bv Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
WO2010072398A2 (en) 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
EP2611445B1 (en) * 2010-09-03 2018-08-15 Zoetis Belgium S.A. High dose buprenorphine compositions and use as analgesic
DK2632468T3 (en) 2010-10-25 2018-02-12 Univ Manitoba THERAPEUTIC COMPOSITIONS FOR SYMMETRIC DIABETIC POLYNEuropathy
US20130115253A1 (en) * 2011-11-07 2013-05-09 Mahendra R. Patel Sustained Release Suspension Preparation For Dextromethorphan
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2014160702A1 (en) * 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
WO2014168925A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
CN108463214A (zh) * 2015-10-27 2018-08-28 因塞斯发展股份有限公司 液体丁丙诺啡制剂
PT3512518T (pt) * 2016-09-13 2023-01-27 Alar Pharmaceuticals Inc Formulações de buprenorfina de libertação prolongada
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
GB201716830D0 (en) * 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
MX2020003697A (es) 2017-10-20 2020-08-13 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
AU2019209416A1 (en) * 2018-01-22 2020-07-30 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
WO2023056043A1 (en) * 2021-09-30 2023-04-06 Elanco Us Inc. Stable formulations of buprenorphine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6384043B1 (en) * 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
IL126251A (en) * 1996-03-25 2003-06-24 Lohmann Therapie Syst Lts Layered system for application of an active substance-releasing layer of small thickness and processes for the production thereof
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
EP1272035A1 (en) * 2000-07-13 2003-01-08 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20040258740A1 (en) * 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition

Also Published As

Publication number Publication date
EP1951240A2 (en) 2008-08-06
KR20080071185A (ko) 2008-08-01
WO2007061828A2 (en) 2007-05-31
US20070117828A1 (en) 2007-05-24
CA2629560A1 (en) 2007-05-31
CN101312730A (zh) 2008-11-26
JP2009516687A (ja) 2009-04-23
NZ568313A (en) 2011-11-25
WO2007061828A3 (en) 2007-07-19
ZA200804355B (en) 2009-04-29
AU2006316607A1 (en) 2007-05-31
ECSP088461A (es) 2008-06-30
US20070116730A1 (en) 2007-05-24
CA2630072A1 (en) 2007-05-31
JP2009516686A (ja) 2009-04-23
PE20070643A1 (es) 2007-08-10
NO20082833L (no) 2008-07-29
WO2007061739A3 (en) 2007-07-12
AR058193A1 (es) 2008-01-23
RU2008124805A (ru) 2009-12-27
EP1954275A2 (en) 2008-08-13
ZA200804305B (en) 2009-04-29
WO2007061739A2 (en) 2007-05-31
BRPI0618891A2 (pt) 2011-09-13

Similar Documents

Publication Publication Date Title
TW200738240A (en) Pharmaceutical compositions
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
IL198687A0 (en) Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
WO2009059048A3 (en) (+)-opioids and methods of use
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
PE20081874A1 (es) Composicion farmaceutica que comprende buprenorfina y naloxona
WO2006081276A8 (en) 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MA32301B1 (fr) 1-aryl-3-amino-alcoxypyrazoles comme ligands de sigma augmentant l'effet analgesique d'opioides et attenuant la dependance a ceux-ci
WO2008063301A3 (en) Pharmaceutical compositions
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
TW200503640A (en) Accelerator for mineral absorption and its usage
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
ITTV20050080A1 (it) Metodo e sistema per distribuire contenuti multimediali.
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych